CoChat

ERRγ enhances cardiac maturation with T-tubule formation in human iPSC-derived cardiomyocytes

Open access
Miki, Kenji, Deguchi, Kohei, Nakanishi-Koakutsu, Misato, Lucena-Cacace, Antonio, Kondo, Shigeru, Fujiwara, Yuya, Hatani, Takeshi, Sasaki, Masako, Naka, Yuki, Okubo, Chikako, Narita, Megumi, Takei, Ikue, Napier, Stephanie C., Sugo, Tsukasa, Imaichi, Sachiko, Monjo, Taku, Ando, Tatsuya, Tamura, Norihisa, Imahashi, Kenichi, Nishimoto, Tomoyuki, Yoshida, Yoshinori · 2021 · Nature Communications

The DOI matches its Crossref record; 36 of the 36 references it cites were found in a registry or an index.

Abstract

Abstract One of the earliest maturation steps in cardiomyocytes (CMs) is the sarcomere protein isoform switch between TNNI1 and TNNI3 (fetal and neonatal/adult troponin I). Here, we generate human induced pluripotent stem cells (hiPSCs) carrying a TNNI1EmGFP and TNNI3mCherry double reporter to monitor and isolate mature sub-populations during cardiac differentiation. Extensive drug screening identifies two compounds, an estrogen-related receptor gamma (ERRγ) agonist and an S-phase kinase-associated protein 2 inhibitor, that enhances cardiac maturation and a significant change to TNNI3 expression. Expression, morphological, functional, and molecular analyses indicate that hiPSC-CMs treated with the ERRγ agonist show a larger cell size, longer sarcomere length, the presence of transverse tubules, and enhanced metabolic function and contractile and electrical properties. Here, we show that ERRγ-treated hiPSC-CMs have a mature cellular property consistent with neonatal CMs and are useful for disease modeling and regenerative medicine.

Overview

The claims and statistics of this paper haven’t been checked yet.

Free: it reads the open-access text and checks the first 5 claims that cite a source we can check. Create a free account to check every claim.

A few free checks a day · papers already verified open instantly · results are public

Integrity signals

Registry

Crossref · 10.1038/s41467-021-23816-3

Cites

36 of 36 references verified0 citation errors · 0 not checkable

Statistics

Figures

Fig. 1 Generation of the hiPSC TNNI1EmGFP and TNNI3mCherry dual reporter. a Schematic for the construction of the reporter cell line and the homologous recombination strategy using the CRISPR/Cas9 system. FAM (6-carboxyfluorescein) and VIC (VIC™ fluorescent dye) are fluorescent probes for ddPCR. b Schematic representation of the TNNI1EmGFP and TNNI3mCherry dual reporter during cardiac differentiation. c ddPCR (FAM probe, blue bars; VIC probe, green bars) of TNNI1EmGFP knock-in clones before and after treatment with piggyBac transposase. d Phase-contrast and EmGFP fluorescence images of hiPSCs (#4-12-20) and day-14 EBs. Scale bars: 500 μm. e Flow cytometric analysis and sorting on day 14 of the differentiation for EmGFP+ cells (top) and the EmGFP+-derived cTNT+ cell fraction (bottom). f Karyotype of the generated TNNI1-EmGFP knockin clone #4-12-20.
Fig. 1 Generation of the hiPSC TNNI1EmGFP and TNNI3mCherry dual reporter. a Schematic for the construction of the reporter cell line and the homologous recombination strategy using the CRISPR/Cas9 system. FAM (6-carboxyfluorescein) and VIC (VIC™ fluorescent dye) are fluorescent probes for ddPCR. b Schematic representation of the TNNI1EmGFP and TNNI3mCherry dual reporter during cardiac differentiation. c ddPCR (FAM probe, blue bars; VIC probe, green bars) of TNNI1EmGFP knock-in clones before and after treatment with piggyBac transposase. d Phase-contrast and EmGFP fluorescence images of hiPSCs (#4-12-20) and day-14 EBs. Scale bars: 500 μm. e Flow cytometric analysis and sorting on day 14 of the differentiation for EmGFP+ cells (top) and the EmGFP+-derived cTNT+ cell fraction (bottom). f Karyotype of the generated TNNI1-EmGFP knockin clone #4-12-20.CC BY · PubMed Central
Fig. 2 Molecular screening for TNNI3mCherry expression. a Schematic representation of the cardiac differentiation protocol for cardiac maturation monitoring. b Bright field (left) and EmGFP fluorescence (right) images of day-14-derived EBs. Scale bars: 500 μm. c Flow cytometric analysis of day-14-derived EBs for TNNI1EmGFP. d Compounds were selected by the median (MED) plus 3 MAD. e Screening outline of the chemical compounds. f High content imaging for mCherry dose-dependency intensity. n = 2 biologically independent samples per group. g Dose-dependent T112-derived fluorescence for TNNI1EmGFP and TNNI3mCherry. Scale bars: 100 μm. h Dose-dependent cell number per well after treatment. n.d. not detected. n = 2 biologically independent samples per group. i Dose-dependent T623-derived fluorescence for TNNI1EmGFP and TNNI3mCherry. Scale bars: 100 μm.
Fig. 2 Molecular screening for TNNI3mCherry expression. a Schematic representation of the cardiac differentiation protocol for cardiac maturation monitoring. b Bright field (left) and EmGFP fluorescence (right) images of day-14-derived EBs. Scale bars: 500 μm. c Flow cytometric analysis of day-14-derived EBs for TNNI1EmGFP. d Compounds were selected by the median (MED) plus 3 MAD. e Screening outline of the chemical compounds. f High content imaging for mCherry dose-dependency intensity. n = 2 biologically independent samples per group. g Dose-dependent T112-derived fluorescence for TNNI1EmGFP and TNNI3mCherry. Scale bars: 100 μm. h Dose-dependent cell number per well after treatment. n.d. not detected. n = 2 biologically independent samples per group. i Dose-dependent T623-derived fluorescence for TNNI1EmGFP and TNNI3mCherry. Scale bars: 100 μm.CC BY · PubMed Central
Fig. 3 T112 and T623 enhanced the cardiac maturation of hiPSC-CMs. a Fluorescence images of day-16-derived EBs for TNNI1EmGFP and TNNI3mCherry expression. Scale bars: 500 μm. NT no treatment, PC positive control. b Flow cytometric analysis of day-16-derived cells for TNNI3mCherry expression. n = 3 independent experiments per group. Data are the mean ± SEM; ****P < 0.0001 compared to DMSO using one-way ANOVA followed by Dunnett’s test. NT no treatment, PC positive control. c Principal-component analysis (PCA) in correlation with the maturation of CMs for more than 58,000 genes expressed in the four groups. Data are shown as average PCA for each group. n = 3 independent experiments per group. d Sample correlation matrix resulting from the consensus clustering analysis of mRNA data and showing transcriptomic differences among treatments. Data are shown as averages for each group. n = 3 independent experiments per group. e Volcano plots for DE genes in accordance with the cardiac maturation phenotype. f Summary of upregulated DE genes in either T623/T112-treated CMs or Combo-treated CMs compared to DMSO. The number of upregulated genes (at least 2-fold) is depicted. Left: 344 unique elements detected in the T623-treated CMs compared to DMSO. Middle: 947 unique elements detected in the T112-treated CMs compared to DMSO. Right: 1254 unique elements detected in the Combo-treated CMs compared to DMSO. g Analysis of the top-6 cardiac-related significant GO terms for the cellular components of T623-, T112- and Combo-treated CMs.
Fig. 3 T112 and T623 enhanced the cardiac maturation of hiPSC-CMs. a Fluorescence images of day-16-derived EBs for TNNI1EmGFP and TNNI3mCherry expression. Scale bars: 500 μm. NT no treatment, PC positive control. b Flow cytometric analysis of day-16-derived cells for TNNI3mCherry expression. n = 3 independent experiments per group. Data are the mean ± SEM; ****P < 0.0001 compared to DMSO using one-way ANOVA followed by Dunnett’s test. NT no treatment, PC positive control. c Principal-component analysis (PCA) in correlation with the maturation of CMs for more than 58,000 genes expressed in the four groups. Data are shown as average PCA for each group. n = 3 independent experiments per group. d Sample correlation matrix resulting from the consensus clustering analysis of mRNA data and showing transcriptomic differences among treatments. Data are shown as averages for each group. n = 3 independent experiments per group. e Volcano plots for DE genes in accordance with the cardiac maturation phenotype. f Summary of upregulated DE genes in either T623/T112-treated CMs or Combo-treated CMs compared to DMSO. The number of upregulated genes (at least 2-fold) is depicted. Left: 344 unique elements detected in the T623-treated CMs compared to DMSO. Middle: 947 unique elements detected in the T112-treated CMs compared to DMSO. Right: 1254 unique elements detected in the Combo-treated CMs compared to DMSO. g Analysis of the top-6 cardiac-related significant GO terms for the cellular components of T623-, T112- and Combo-treated CMs.CC BY · PubMed Central
Fig. 4 Transcriptomic pathways and gene sets enrichment. a Reactome pathway analysis for T623-, T112- and Combo-treated CMs. Enriched pathways were calculated using the binomial test over DE genes between individual conditions compared to DMSO. The top 15 statistically significant pathways are listed. P-values are displayed as logarithmic form (log). b Gene set analysis of cardiac maturation-specific genes.
Fig. 4 Transcriptomic pathways and gene sets enrichment. a Reactome pathway analysis for T623-, T112- and Combo-treated CMs. Enriched pathways were calculated using the binomial test over DE genes between individual conditions compared to DMSO. The top 15 statistically significant pathways are listed. P-values are displayed as logarithmic form (log). b Gene set analysis of cardiac maturation-specific genes.CC BY · PubMed Central
Fig. 5 Metabolic and structural functionality of hiPSC-CMs. a Mitochondrial respiration rates of hiPSC-CMs treated with DMSO (n = 4), T112 (n = 5), T623 (n = 5), or Combo (n = 5) (O, Oligomycin; F, FCCP, phenylhydrazone; AR, Antimycin A and Rotenone). n = biologically independent samples per group. Data are the mean ± SEM. b Basal and maximal OCR and ATP production of hiPSC-CMs treated with DMSO (n = 4), T112 (n = 5), T623 (n = 5), or Combo (n = 5). n = biologically independent samples per group. Data are the mean ± SEM. Statistical analysis was compared to DMSO using one-way ANOVA followed by Dunnett’s test. ****P < 0.0001. c top: Representative western blots of cTnI, ssTnI, and GAPDH proteins in hiPSC-CMs treated with DMSO, T112, T623, or Combo. For ssTnI, two bands were detected: the shorter one is wild type ssTnI and the longer one is ssTnI with F2A peptides. Bottom: cTnI/ssTnI relative ratio. n = 3 independent experiments per group. Data are the mean ± SEM. Statistical analysis was compared to DMSO using one-way ANOVA followed by Dunnett’s test. d Cell area of hiPSC-CMs treated with DMSO, T112, or T623 measured by high content imaging. For each group, n = 300 cells over three independent experiments. e Roundness of hiPSC-CMs treated with DMSO, T112, T623, or Combo. Each group, n = 3 independent experiments. Data are the mean ± SEM. Statistical analysis was done using one-way ANOVA followed by Tukey’s HSD test. f Sarcomere length in hiPSC-CMs treated with DMSO, T112, T623, or Combo. Boxes represent 25th–75th percentiles; whiskers represent the minimum and maximum ranges; horizontal lines indicate the median values. n = 15, one measurement per TEM image from 15 TEM images over two consecutive experiments; ****P < 0.0001 compared to DMSO, ‡P < 0.0001 compared to T623 using one-way ANOVA followed by Tukey’s HSD test. g Contractile properties of hiPSC-CMs treated with DMSO (n = 6), T112 (n = 7), T623 (n = 5), or Combo (n = 9). Top: Contraction velocity. Middle: Relaxation velocity. n = biologically independent samples examined over three independent experiments. bottom: Maximum conduction velocity. n = 3 independent experiments. Statistical analysis was compared to DMSO using one-way ANOVA followed by Dunnett’s test. ****P < 0.0001. h Representative AP recorded from hiPSC-CMs treated with DMSO or T112. i The fraction of APs with a notch (black). j Electrophysiology data of APA, Vmax and MDP in hiPSC-CMs treated with DMSO (n = 21) or T112 (n = 18) over 3 independent experiments. Boxes represent 25th–75th percentiles; whiskers represent the minimum and maximum ranges; horizontal lines indicate the median values. Statistical analysis was done using unpaired two-tailed t-test. k Typical high magnification TEM images of hiPSC-CMs treated with T112 or Combo. Scale bars: 500 nm. I: I-band; TT: T-tubule; Z: Z line.All results are from #8-5-3.
Fig. 5 Metabolic and structural functionality of hiPSC-CMs. a Mitochondrial respiration rates of hiPSC-CMs treated with DMSO (n = 4), T112 (n = 5), T623 (n = 5), or Combo (n = 5) (O, Oligomycin; F, FCCP, phenylhydrazone; AR, Antimycin A and Rotenone). n = biologically independent samples per group. Data are the mean ± SEM. b Basal and maximal OCR and ATP production of hiPSC-CMs treated with DMSO (n = 4), T112 (n = 5), T623 (n = 5), or Combo (n = 5). n = biologically independent samples per group. Data are the mean ± SEM. Statistical analysis was compared to DMSO using one-way ANOVA followed by Dunnett’s test. ****P < 0.0001. c top: Representative western blots of cTnI, ssTnI, and GAPDH proteins in hiPSC-CMs treated with DMSO, T112, T623, or Combo. For ssTnI, two bands were detected: the shorter one is wild type ssTnI and the longer one is ssTnI with F2A peptides. Bottom: cTnI/ssTnI relative ratio. n = 3 independent experiments per group. Data are the mean ± SEM. Statistical analysis was compared to DMSO using one-way ANOVA followed by Dunnett’s test. d Cell area of hiPSC-CMs treated with DMSO, T112, or T623 measured by high content imaging. For each group, n = 300 cells over three independent experiments. e Roundness of hiPSC-CMs treated with DMSO, T112, T623, or Combo. Each group, n = 3 independent experiments. Data are the mean ± SEM. Statistical analysis was done using one-way ANOVA followed by Tukey’s HSD test. f Sarcomere length in hiPSC-CMs treated with DMSO, T112, T623, or Combo. Boxes represent 25th–75th percentiles; whiskers represent the minimum and maximum ranges; horizontal lines indicate the median values. n = 15, one measurement per TEM image from 15 TEM images over two consecutive experiments; ****P < 0.0001 compared to DMSO, ‡P < 0.0001 compared to T623 using one-way ANOVA followed by Tukey’s HSD test. g Contractile properties of hiPSC-CMs treated with DMSO (n = 6), T112 (n = 7), T623 (n = 5), or Combo (n = 9). Top: Contraction velocity. Middle: Relaxation velocity. n = biologically independent samples examined over three independent experiments. bottom: Maximum conduction velocity. n = 3 independent experiments. Statistical analysis was compared to DMSO using one-way ANOVA followed by Dunnett’s test. ****P < 0.0001. h Representative AP recorded from hiPSC-CMs treated with DMSO or T112. i The fraction of APs with a notch (black). j Electrophysiology data of APA, Vmax and MDP in hiPSC-CMs treated with DMSO (n = 21) or T112 (n = 18) over 3 independent experiments. Boxes represent 25th–75th percentiles; whiskers represent the minimum and maximum ranges; horizontal lines indicate the median values. Statistical analysis was done using unpaired two-tailed t-test. k Typical high magnification TEM images of hiPSC-CMs treated with T112 or Combo. Scale bars: 500 nm. I: I-band; TT: T-tubule; Z: Z line.All results are from #8-5-3.CC BY · PubMed Central
Fig. 6 Stage-specific causal role of ERRγ in regulating TNNI3-driven cardiac maturation. a Fluorescence images of ERRγKO hiPSC-CMs treated with DMSO, T112, or T623 for TNNI1EmGFP and TNNI3mCherry expression. Scale bars: 500 μm. b Flow cytometric analysis of day-16 CMs derived from ERRγKO hiPSCs for TNNI3mCherry expression. n = 4 independent experiments per group. Data are the mean ± SEM; Statistical analysis was compared to DMSO using one-way ANOVA followed by Dunnett’s test. NT no treatment. c Mitochondrial respiration rates of ERRγKO hiPSC-CMs treated with either DMSO or T112 (O Oligomycin; F FCCP, phenylhydrazone; AR Antimycin A and Rotenone). n = 5 biologically independent samples per group. d Basal and maximal OCR and ATP production of ERRγKO hiPSC-CMs treated with either DMSO or T112. Statistical analysis was done using unpaired two-tailed t-tests. n = 5 biologically independent samples per group. Data are the mean ± SEM; Statistical analysis was using unpaired two-tailed t-test.
Fig. 6 Stage-specific causal role of ERRγ in regulating TNNI3-driven cardiac maturation. a Fluorescence images of ERRγKO hiPSC-CMs treated with DMSO, T112, or T623 for TNNI1EmGFP and TNNI3mCherry expression. Scale bars: 500 μm. b Flow cytometric analysis of day-16 CMs derived from ERRγKO hiPSCs for TNNI3mCherry expression. n = 4 independent experiments per group. Data are the mean ± SEM; Statistical analysis was compared to DMSO using one-way ANOVA followed by Dunnett’s test. NT no treatment. c Mitochondrial respiration rates of ERRγKO hiPSC-CMs treated with either DMSO or T112 (O Oligomycin; F FCCP, phenylhydrazone; AR Antimycin A and Rotenone). n = 5 biologically independent samples per group. d Basal and maximal OCR and ATP production of ERRγKO hiPSC-CMs treated with either DMSO or T112. Statistical analysis was done using unpaired two-tailed t-tests. n = 5 biologically independent samples per group. Data are the mean ± SEM; Statistical analysis was using unpaired two-tailed t-test.CC BY · PubMed Central
Fig. 7 hiPSC cardiac maturation model. Schematic representation of an ERRγ agonist inducing the cardiac neonatal-like phenotype.
Fig. 7 hiPSC cardiac maturation model. Schematic representation of an ERRγ agonist inducing the cardiac neonatal-like phenotype.CC BY · PubMed Central

Verification

Claims the paper makes

The claims and statistics of this paper haven’t been checked yet.

Free: it reads the open-access text and checks the first 5 claims that cite a source we can check. Create a free account to check every claim.

A few free checks a day · papers already verified open instantly · results are public

Claims other papers make about this one

Each is checked against this paper’s own text: does it say what the citing paper says it does?

Self-check

Percentages, sums and reported differences re-computed from the paper’s own numbers.

The self-check needs the paper’s full text.

Citations

Cites

Show all 36 references

Cited by

See all 76

Metadata

Authors
Miki, K., Deguchi, K., Nakanishi-Koakutsu, M., Lucena-Cacace, A., Kondo, S., Fujiwara, Y., Hatani, T., Sasaki, M., Naka, Y., Okubo, C., Narita, M., Takei, I., Napier, S. C., Sugo, T., Imaichi, S., Monjo, T., Ando, T., Tamura, N., Imahashi, K., Nishimoto, T., & Yoshida, Y.
Affiliations
  • Kyoto University (JP)
  • Takeda (Japan) (JP)
Corresponding author
  • Nishimoto, Tomoyuki
  • Yoshida, Yoshinori
Venue
Nature Communications
Published
2021-06-21
Volume
12
Issue
1
Pages
3596-3596
ISSN
2041-1723 (ISSN-L)
OpenAlex
W3175941182
Cited by
76
References
36
Citations by year
2026: 10 · 2025: 18 · 2024: 17 · 2023: 15 · 2022: 14 · 2021: 2
FWCI
3.76
Type
journal article
Language
en
Open access
Licence
Locations
  • Nature Communications (publishedVersion, cc-by)
  • PubMed Central (publishedVersion, cc-by)
  • PubMed (publishedVersion)
  • Institutional Repositories DataBase (IRDB) (submittedVersion)
  • Kyoto University Research Information Repository (Kyoto University) (submittedVersion, cc-by)
  • RePEc: Research Papers in Economics (submittedVersion)
  • DOAJ (DOAJ: Directory of Open Access Journals) (submittedVersion, cc-by-sa)
Funders
  • MEXT | Japan Society for the Promotion of Science (18K15120, 18KK0461, 17H04176)
  • Japan Agency for Medical Research and Development (19bm0104001h0007, 19bm0204003h0107, 19bm0804008h0103, 20bm0804022h0001, 19bk0104095h0001)
  • Fondation Leducq (18CVD05)
  • a grant from Takeda Pharmaceutical Company Limited SECOM Science and Technology Foundation
Topics
  • Life Sciences › Biochemistry, Genetics and Molecular Biology › Molecular Biology › Pluripotent Stem Cells Research
  • Life Sciences › Biochemistry, Genetics and Molecular Biology › Molecular Biology › Congenital heart defects research
  • Health Sciences › Medicine › Cardiology and Cardiovascular Medicine › Cardiac electrophysiology and arrhythmias
Keywords
estrogen-related receptor gamma, cardiac maturation, TNNI3, iPSC-derived cardiomyocytes, sarcomere length, cardiac differentiation, cardiomyocyte contractility, cardiomyocyte electrophysiology, metabolic function, disease modeling, regenerative medicine
MeSH terms
Cell Differentiation, Gene Expression Regulation, Humans, Models, Biological, Receptors, Estrogen, Sarcolemma, Sarcomeres, Genes, Reporter, Troponin I, Myocytes, Cardiac, S-Phase Kinase-Associated Proteins, Induced Pluripotent Stem Cells, Transcriptome

About these checks

Registry, retraction, Cites and statistics results are computed, not judged, with one exception: a printed reference that no index lists is read once by a model before it counts as a citation error. Claims are extracted by a model and kept only when their quote appears verbatim in the text; each cited source is then checked, with a model’s help, for whether it says what the claim relies on. Those verdicts can be wrong — read the claim’s quote and the cited source before relying on one.

Statistics and arithmetic are recomputed, not judged.

Confidence bands are shown only for fields calibrated on our annotated test set. None is calibrated yet, so no band is shown.

What counts as a claim ›How we measure confidence ›How we check this ›

Are you an author, or do you see a problem with this page? Request a review

How to cite

Cite CoChat for the checks on this page, and the paper for its own findings.

This page
CoChat. (2026). Citation check: ERRγ enhances cardiac maturation with T-tubule formation in human iPSC-derived cardiomyocytes. https://app.cochat.ai/papers/10.1038/s41467-021-23816-3
The paper
Miki, K., Deguchi, K., Nakanishi-Koakutsu, M., Lucena-Cacace, A., Kondo, S., Fujiwara, Y., Hatani, T., Sasaki, M., Naka, Y., Okubo, C., Narita, M., Takei, I., Napier, S. C., Sugo, T., Imaichi, S., Monjo, T., Ando, T., Tamura, N., Imahashi, K., . . . Yoshida, Y. (2021). ERRγ enhances cardiac maturation with T-tubule formation in human iPSC-derived cardiomyocytes. Nature Communications. https://doi.org/10.1038/s41467-021-23816-3

Data sources

Bibliographic data: Semantic Scholar, OpenAlex, Crossref.

Contains information from the Semantic Scholar Academic Graph Datasets, made available under the ODC Attribution License (ODC-BY 1.0).

Semantic Scholar’s data is described in: Kinney, R., et al. (2023). The Semantic Scholar Open Data Platform. arXiv:2301.10140.